Amie Phinney
Vermögen: 44 600 $ am 31.05.2026
Vermögen: 44 600 $ am 31.05.2026
Amie Phinney is the founder of Block Biosciences, Inc. Currently, Dr. Phinney is Director & Head-Strategy at Defence Therapeutics Inc since 2025.
Formerly, Dr. Phinney was Senior Director-Partnerships at adMare Bioinnovations from 2021 to 2024.
Education includes undergraduate studies at the University of Guelph, graduate studies at the University of Basel, and an MBA from Lake Forest Graduate School of Management.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 10.12.2025 | 100’000 ( 0.13% ) | 44 600 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| DEFENCE THERAPEUTICS INC. | Direktor/Vorstandsmitglied | 16.09.2025 |
| Unternehmen | Position | Ende |
|---|---|---|
adMare Bioinnovations
adMare Bioinnovations Miscellaneous Commercial ServicesCommercial Services adMare Bioinnovations engages in the provision of research for its academic and biotech partners. The company was founded in 2011 and is headquartered in Vancouver, Canada. | Corporate Officer/Principal | 01.09.2024 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
| Private Unternehmen | 5 |
|---|---|
University of Guelph
University of Guelph Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Basel
University of Basel Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lake Forest Graduate School of Management
Lake Forest Graduate School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
adMare Bioinnovations
adMare Bioinnovations Miscellaneous Commercial ServicesCommercial Services adMare Bioinnovations engages in the provision of research for its academic and biotech partners. The company was founded in 2011 and is headquartered in Vancouver, Canada. | Commercial Services |
Defence Therapeutics Inc
Defence Therapeutics Inc Pharmaceuticals: MajorHealth Technology Engages in the research and development of anti-body drug conjugates | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen